Saluda Medical raises $100M Series D to scale ECAP closed-loop SCS globally following RCT superiority data
Summary
Saluda Medical closed $100M in Series D financing to support global commercial expansion of Evoke — the world's first SCS system using Evoked Compound Action Potential (ECAP) measurement to automatically optimize stimulation in real time. Multiple RCTs have demonstrated Evoke superiority over conventional open-loop SCS for chronic pain. The round brings total funding to $220M+ and will fund expansion from Australia to US, European, and Asian markets.
Why it matters
Saluda raising $100M on the back of demonstrated RCT superiority makes this one of the most de-risked commercial scale rounds in neuromodulation history. The risk is commercial execution — building a global sales force, achieving insurance coverage, and converting DBS/SCS centers from traditional devices — not technology risk, which the RCT data has resolved.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial